Le WIR en Suisse : la révolte du puissant ? by Guillaume Vallet

Subjects: Get full text

A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland by Tämer El Saadany, Judith Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

“…Because the price of sotorasib has not been established in Switzerland, two scenarios were analysed: the first used the published expected monthly United Kingdom (UK) price in Swiss francs (CHF 7870); the second used one-quarter of that price (CHF 1968), according to the lower dose used in the most recent trial, under the condition that one-quarter of the original sotorasib dose is equally effective. …”
Get full text